Name: Detection and Removal of Nuclease Contamination During Purification of Recombinant Prototype Foamy Virus Integrase (Video) | JoVE Journal
Uploaded: 2017-12-08T14:00:00.000+00:00
Duration: 7 min 50 s
Description: Learn to detect and remove nuclease contamination during purification of recombinant prototype foamy virus integrase from Escherichia coli. This protocol uses heparin affinity chromatography and a nuclease assay to ensure nuclease-free protein for accurate biochemical and single-molecule studies of retroviral integration.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This work was supported by NIH AI099854 and AI126742 to KEY.

1. Induce PFV IN Expression in E. coli
<ol>
	<li>Add 1 &#956;L of PFV IN expression plasmid (10 ng/&#956;L) to 20 &#956;L of E. coli BL21(DE3) pLysS (20 &#956;L aliquot of commercially available cells has &#62;2 x 106 CFU/&#956;g plasmid) in a 1.5 mL tube. Mix gently by finger tapping or flicking the tube. Incubate on ice 5 min.
	<ol>
		<li>Heat shock for exactly 30 s in a 42 &#730;C water bath and then immediately return to ice for 2 min.</li>
		<li>Add 80 &#956;L of room temperature super optimal broth with catabolite repression (SOC) media. Incubate for 1 h at 37 &#730;C with 225 revolutions per minute (rpm) shaking.</li>
		<li>Plate 25 &#956;L of the mixture on a 100 mm x 15 mm Petri dish containing 25 mL of Luria broth (LB) agar (1 L LB agar: 10 g bacto-tryptone, 10 g NaCl, 5 g yeast extract, 15 g agar) and 100 &#956;g/mL ampicillin (100 mg/mL stock solution).</li>
		<li>Plate the remaining 75 &#956;L of the transformed cells on a second identical plate. Incubate the plates with the lids down overnight at 37 &#176;C.</li>
	</ol>
	</li>
	<li>Retrieve the plates of transformed E. coli. Use a single colony to inoculate 3 mL of LB (1 L LB: 10 g of bacto-tryptone, 10 g of NaCl, 5 g of yeast extract) supplemented with 100 &#956;g/mL ampicillin in a 14-mL round bottom polypropylene culture tube. Incubate for ~8 h at 37 &#730;C with 225 rpm shaking.
	<ol>
		<li>Add the 3 mL of culture to 50 mL LB supplemented with 100 &#956;g/mL ampicillin and 34 &#956;g/mL chloramphenicol (34 mg/mL stock solution) in a 250 mL Erlenmeyer flask. Incubate the culture overnight at 37 &#176;C with 225 rpm shaking.</li>
		<li>Transfer the 53 mL of culture to 1 L LB, 100 &#956;g/mL ampicillin, and 34 &#956;g/mL chloramphenicol in a 4 L Erlenmeyer flask. Incubate at 37 &#176;C with 225 rpm shaking.</li>
		<li>Measure the optical density at 600 nm (OD600) of the culture periodically. Initially, check the culture OD600 every h. As the culture reaches the desired OD600, check every 15 min to not overgrow. Grow the culture to an OD600 between 0.9 and 1.0. Transfer the flask to an ice bath and swirl to reduce the temperature of the culture.</li>
	</ol>
	</li>
	<li>Transfer 1 mL of the culture to a 1.5 mL tube for later analysis by denaturing SDS-PAGE analysis.
	<ol>
		<li>Pellet the cells in the 1.5 mL tube by centrifugation for 1 min in a microfuge at 14,000 x g at room temperature. Discard the supernatant. Resuspend the pellet in 150 &#956;L phosphate buffered saline (PBS) by pipetting. The PBS may be either with or without CaCl2 and MgCl2.</li>
		<li>Add 150 &#956;L of 2x SDS-PAGE sample buffer (150 mM Tris-HCl, pH 6.8, 1.2% SDS, 30% glycerol, 15% &#946;-mercaptoethanol (&#946;ME), 0.0018% bromophenol blue) and mix thoroughly by pipet or vortex. Boil for 3 min. Store at -20 &#176;C.</li>
	</ol>
	</li>
	<li>Add to the bacterial culture: a final concentration of 0.25 mM isopropyl-beta-D-thiogalactopyranoside (IPTG, 0.25 M stock solution) and 50 &#956;M ZnCl2 (50 mM stock solution). IPTG induces expression of the PFV IN gene from the T7 promoter and ZnCl2 is added as a supplement for the correct folding of an amino terminal zinc finger domain in PFV IN. Incubate the culture at 25 &#176;C with shaking at 225 rpm for 4 h. Immediately transfer the flask to an ice bath. Save 1 mL of culture for SDS-PAGE analysis following the same protocol as above in 1.3.</li>
	<li>Transfer the bacterial culture to appropriately sized centrifuge bottles. For example, a 1 L culture may be transferred to four sterile disposable 250 mL conical bottom polypropylene bottles. Spin the bottles in a refrigerated tabletop centrifuge at 3000 x g for 20 min at 4 &#730;C. Discard supernatants by pouring.
	<ol>
		<li>Resuspend all of the pellets from a 1 L bacterial culture in a total volume of 25 mL (6.25 mL per bottle) cold PBS (with or without CaCl2 and MgCl2) by pipetting. Combine and transfer the bacterial suspensions to one 50 mL conical tube. Spin in a refrigerated centrifuge at 3,000 x g for 20 min at 4 &#176;C. Discard the supernatant by pouring or pipetting.</li>
	</ol>
	</li>
	<li>Resuspend the bacterial pellet in 10 mL resuspension buffer (50 mM Tris-HCl, pH 7.5, 500 mM NaCl, and 500 &#956;M phenylmethylsulfanoxide (PMSF) protease inhibitor) by pipetting. Snap freeze the pellet by placing the tube in a Dewar flask with liquid nitrogen sufficient to submerge the 50 mL tube. Carefully remove the tube from liquid nitrogen and store at -80 &#176;C. 
	Note: Bacterial pellets may be stored for several months at -80 &#176;C. We have seen no loss of active protein following -80 &#176;C storage for two years.</li>
	<li>Analyze the pre-induction and post-induction samples by 8.3 cm wide, 7.3 cm high, 0.75 mm thick SDS-PAGE gels with 1.5 mL 6% polyacrylamide stacking layer (125 mM Tris-HCl, pH 6.8, 6% acrylamide, 0.1% SDS, 0.1% ammonium persulfate, 0.001% TEMED) and 3.5 mL 10% polyacrylamide resolving layer (375 mM Tris-HCl, pH 8.8, 10% acrylamide, 0.1% SDS, 0.1% ammonium persulfate, 0.001% TEMED)12.
	<ol>
		<li>After pouring the stacking gel, insert a 10 well comb. When the gel has polymerized, assemble the PAGE apparatus, and add sufficient SDS-PAGE running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS).</li>
		<li>Load 10 &#956;L of each sample and 4 &#956;L of prestained protein standards. Run at 16.5 V/cm until the dye front reaches the bottom of the gel, approximately 60 min.</li>
		<li>Disassemble the gel plates and transfer the gel to a plastic tub. Add Coomassie Brilliant Blue staining solution (0.1% Coomassie brilliant blue R-250, 40% methanol, 10% acetic acid) to generously cover the gel and stain for 20 min at ambient temperature.</li>
		<li>Remove the staining solution by pouring and replace with destain solution (40% methanol, 10% acetic acid) until bands are readily visible. Remove the destaining solution by pouring and replace with deionized water. PFV IN should be easily identified in the post-induction sample. PFV IN with a hexahistidine tag has a molecular weight of 47374 Da.</li>
		<li>If PFV IN is not visible, repeat the induction starting with a different colony from one of the transformation plates.</li>
	</ol>
	</li>
</ol>
2. Nickel Affinity Chromatography
<ol>
	<li>Thaw one bacterial pellet on ice. 
	Note: This will take significant time (approximately 2 - 3 h). When the pellet has thawed to a cell slurry, add an additional 500 &#956;M PMSF (100 mM stock solution).</li>
	<li>Keep the 50 mL tube of bacteria slurry on ice. Sonicate the bacteria at 30% amplitude for 30 s (1 s on, 1 s off) per pellet derived from 1 L culture using a sonicator with a 0.5 inch diameter bio horn with a 0.125 inch diameter tapered microtip, a frequency of 20 kHz and maximum power of 400 W.</li>
	<li>Transfer the cell sample to a cold ultracentrifuge tube. Use polycarbonate bottle assemblies (25 mm diameter, 89 mm height) compatible with a Type 60 Ti fixed angle rotor. Alternative tubes and rotors may be used if the same gravitation force is achieved. Spin 120,000 x g for 60 min at 4 &#176;C. There should be an obvious pellet. The supernatant may have a yellow color.</li>
	<li>Transfer the supernatant by pouring or pipetting to a cold 50 mL conical tube. Note the volume; this volume should be approximately the volume of resuspension buffer used prior to snap freezing. If the supernatant is viscous, it may be contaminated by bacterial DNA which could clog the chromatography column. In this case, repeat the ultracentrifugation to pellet the bacterial DNA.</li>
	<li>Prepare 500 mL Buffer A (50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 500 &#956;M PMSF) and 500 mL Buffer B (50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 500 &#956;M PMSF, 200 mM imidazole). 
	Note: In this protocol, keep the fast protein liquid chromatography (FPLC) system, all buffers and the sample at 4 &#176;C in a cold room.
	<ol>
		<li>Sterile filter Buffers A and B with 0.2 &#956;m disposable filter units. Depending on the FPLC system, wash pump A and pump B with Buffer A and Buffer B, respectively. Flow 90% Buffer A and 10% Buffer B through the system until the conductivity and UV readings stabilize. The maximum flow rate will depend on the instrument; use a flow rate of 5 mL/min with a maximum pressure limit of 1.0 MPa.</li>
	</ol>
	</li>
	<li>Prepare a 110 mm long, 5 mm diameter FPLC column with 1.5 mL nickel-charged resin (maximum binding capacity 50 mg/mL, maximum pressure 1 MPa). The column may be prepared the day before purification and stored at 4 &#730;C.</li>
	<li>Connect the column to the FPLC instrument. Equilibrate the column with 20 mL of 90% Buffer A and 10% Buffer B (20 mM imidazole) at a flow rate of 0.5 mL/min with a maximum pressure limit of 0.5 MPa. The instrument should be collecting real time data of conductivity and UV absorbance at 280 nm (A280). The conductivity and UV readings should stabilize. If these readings have not stabilized, continue to flow buffers through the column until they are stable.</li>
	<li>Load the protein sample (~10 mL per pellet) to the column at a flow rate of 0.15 mL/min with a maximum pressure limit of 0.5 MPa. The flow rate and column pressure remains the same throughout the purification. Collect the flow through in a 50 mL tube.
	<ol>
		<li>Wash the column with 20 mL 90% Buffer A and 10% Buffer B. Collect the wash in a 50 mL tube. Elute the proteins with a 20 mL linear gradient of 10% to 100% Buffer B (20 mM to 200 mM imidazole).</li>
		<li>Finally, wash the column with 5 mL 100% Buffer B (200 mM imidazole). Collect the gradient and final wash in 0.27 mL fractions.</li>
	</ol>
	</li>
	<li>Combine 15 &#956;L of 2x SDS-PAGE sample buffer with 15 &#956;L of the flow through, wash, and peak A280 fractions. Boil the samples for 3 min.
	<ol>
		<li>Prepare two 10% SDS-PAGE gels as described previously in step 1.6 except with 15 well combs. Load 10 &#956;L of each sample to the gels and 4 &#956;L of prestained protein standards. Run, stain, and analyze the gels as described in step 1.6.</li>
		<li>Combine fractions that appear to contain nearly pure PFV IN based on visual inspection. Measure the volume by pipetting, typically 8 - 10 mL.</li>
		<li>Using a spectrophotometer, measure the A280 of the combined fractions and calculate the total amount of PFV IN protein; our typical yield is ~10 mg per L of induced culture. The extinction coefficient of PFV IN with the hexahistidine tag is 59360 cm-1 M-1.</li>
	</ol>
	</li>
	<li>To remove the hexahistidine tag, supplement the PFV IN with 10 mM dithiothreitol (DTT, 1 M stock solution) and 0.1 mM EDTA, pH 8.0 (0.5 M stock solution). Add 15 &#956;g of human rhinovirus (HRV) 3C protease per mg PFV IN. Incubate at 4 &#730;C overnight. Cleavage reduces the PFV IN molecular weight from 47374 Da to 44394 Da and may be verified by 10% SDS-PAGE analysis.</li>
</ol>
3. Heparin affinity chromatography
<ol>
	<li>Prepare 250 mL Buffer C (50 mM Tris-HCl, pH 7.5, 10 mM DTT, 0.1 mM EDTA, 500 &#956;M PMSF) and 250 mL Buffer D (50 mM Tris-HCl, pH 7.5, 10 mM DTT, 0.1 mM EDTA, 500 &#956;M PMSF, 1 M NaCl). 
	Note: In this protocol, the FPLC system, buffers, and sample are kept in a cold room at 4 &#730;C.
	<ol>
		<li>Sterile filter Buffers C and D with 0.2 &#956;m disposable filter units. Depending on the FPLC system, wash pump A and pump B with Buffer C and Buffer D, respectively. Flow 80% Buffer C and 20% Buffer D through the system until the conductivity and UV readings stabilize. The maximum flow rate will depend on the instrument; we routinely use a flow rate of 5 mL/min with a maximum pressure limit of 1.0 MPa.</li>
	</ol>
	</li>
	<li>Prepare an 80 mm long, 5 mm diameter FPLC column with 1 mL of heparin sepharose resin (maximum binding capacity 2.0 mg of bovine antithrombin III per mL resin; maximum pressure 1.4 MPa). The column may be prepared the day before purification and stored at 4 &#176;C. Connect the column to the FPLC instrument.
	<ol>
		<li>Equilibrate the column with 20 mL of 80% Buffer C and 20% Buffer D (200 mM NaCl) at a flow rate of 0.5 mL/min with a maximum pressure limit of 1 MPa. The instrument should be collecting real time data of conductivity and UV absorbance at 280 nm (A280). The conductivity and UV readings should stabilize. If these readings have not stabilized, continue to flow buffers through the column until they are stable.</li>
	</ol>
	</li>
	<li>Reduce the NaCl concentration of the PFV IN sample to 200 mM by adding 1.5 volumes Buffer C. For example, add 15 mL of Buffer C to 10 mL PFV IN. Our total volume is typically ~25 mL.</li>
	<li>Load the diluted PFV IN sample to the heparin sepharose column at 0.5 mL/min flow rate with maximum pressure limit 1.0 MPa. The flow rate and column pressure remains the same throughout the purification. Collect the flow through in a 50 mL conical tube.
	<ol>
		<li>Wash the column with 20 mL of 80% Buffer C and 20% Buffer D (200 mM NaCl), collecting the wash in a 50 mL conical tube. Elute the column with a 30 mL linear gradient of 20% to 100% Buffer D (200 mM to 1 M NaCl).</li>
		<li>Wash the column with 5 mL of 100% Buffer D. Collect the gradient and final wash in 0.37 mL fractions.</li>
	</ol>
	</li>
	<li>Analyze load, flow through, wash, and fractions by 8% SDS-PAGE as described in 2.9. PFV IN following cleavage of the hexahistidine tag has a molecular weight of 44394 Da and the extinction coefficient remains 59360 cm-1 M-1 without the hexahistidine tag. Store all fractions at 4 &#730;C until the completion of a nuclease assay.</li>
</ol>
4. Nuclease assay
<ol>
	<li>Identify heparin sepharose fractions that appear to contain nearly pure PFV IN. Combine 3 &#956;L of heparin fraction and 50 ng of 3 kb supercoiled plasmid DNA in reaction buffer (10 mM HEPES, pH 7.5, 110 mM NaCl, 5 mM MgSO4, 4 &#956;M ZnCl2, 10 mM DTT) with a final volume of 15 &#956;L. Incubate at 37 &#730;C for 90 min. Include a negative control with no PFV IN.
	<ol>
		<li>Stop the reaction with 1 mg/mL proteinase K (20 mg/mL stock solution) and 0.5% SDS (10% stock solution). Incubate at 37 &#176;C for 1 h. Samples may be stored at -20 &#176;C for later analysis.</li>
	</ol>
	</li>
	<li>Prepare a 125 mL gel of 1% weight per volume (w/v) agarose in 1x&#160;TAE buffer (40 mM Tris-acetate, 1 mM EDTA) with 0.1 &#181;g/mL ethidium bromide (10 mg/mL stock solution)13. Melt the agarose solution and pour to a 15 cm x 10 cm gel casting tray. Insert a 15 well comb with 5 mm wide, 0.75 mm thick wells. Thin wells yield better band resolution compared to 1.5 mm thick wells. Allow the gel to solidify at ambient temperature.
	<ol>
		<li>Immerse the gel in 1x&#160;TAE with 0.1 &#181;g/mL ethidium bromide. Add 3.5 &#956;L of 6x loading dye (50% glycerol, 0.15% Orange G dye) to the nuclease assay reactions. Load the entire volume to the gel. Run the gel at constant voltage, 10 volts per cm (100 V) at ambient temperature for 1 h or until the Orange G dye front reaches the end of the gel.</li>
	</ol>
	</li>
	<li>Immediately image the agarose gel with a fluorescent scanner set to detect ethidium bromide. Linear DNA should run true to size at 3 kb, supercoiled DNA should run faster (~2 kb), and relaxed circle DNA should run slower (~3.5 kb).
	<ol>
		<li>Using image analysis software, calculate the pixel volume of the supercoiled, linear, and relaxed circle plasmid in each lane. Call the sum of the pixel volumes for these three DNA forms the &#34;total DNA&#34; value and use it to calculate the percentage of linear and relaxed circles. For example, the pixel volume of relaxed circles is divided by the total DNA pixel value in that lane, multiply this number by 100 to determine a percentage. Fractions that contain contaminating nuclease display a higher percentage of linear and relaxed circles compared to the negative control.</li>
	</ol>
	</li>
	<li>Combine heparin sepharose fractions that do not display contaminating nuclease activity. Dialyze in 10 mm 6 - 8 kDa molecular weight cutoff (MWCO) dialysis tubing at 4 &#176;C overnight against 1 L of 50 mM Tris-HCl, pH 7.5, 200 mM NaCl, 50 &#956;M ZnCl2, 10 mM DTT, 20% glycerol.</li>
	<li>Recover the nuclease-free PFV IN sample from dialysis tubing. Measure the A280 and calculate the final protein concentration. Aliquot and snap freeze in liquid nitrogen. Store aliquots at -80 &#176;C.</li>
</ol>

<ol><li>Lopez, M. A. Jr, Mackler, R. M., Yoder, K. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Removal+of+nuclease+contamination+during+purification+of+recombinant+prototype+foamy+virus+integrase%5BTitle%5D)+AND+%22J+Virol+Methods%22%5BJournal%5D)">Removal of nuclease contamination during purification of recombinant prototype foamy virus integrase.</a> J Virol Methods. 235, 134-138 (2016).</li>
<li>Senavirathne, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Widespread+nuclease+contamination+in+commonly+used+oxygen-scavenging+systems%5BTitle%5D)+AND+%22Nat+Methods%22%5BJournal%5D)">Widespread nuclease contamination in commonly used oxygen-scavenging systems.</a> Nat Methods. 12 (10), 901-902 (2015).</li>
<li>Gunn, K. H., Marko, J. F., Mondragon, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((An+orthogonal+single-molecule+experiment+reveals+multiple-attempt+dynamics+of+type+IA+topoisomerases%5BTitle%5D)+AND+%22Nat+Struct+Mol+Biol%22%5BJournal%5D)">An orthogonal single-molecule experiment reveals multiple-attempt dynamics of type IA topoisomerases.</a> Nat Struct Mol Biol. 24 (5), 484-490 (2017).</li>
<li>Valkov, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Functional+and+structural+characterization+of+the+integrase+from+the+prototype+foamy+virus%5BTitle%5D)+AND+%22Nucleic+Acids+Res%22%5BJournal%5D)">Functional and structural characterization of the integrase from the prototype foamy virus.</a> Nucleic Acids Res. 37 (1), 243-255 (2009).</li>
<li>Coffin, J. M., Hughes, S. H., Varmus, H. E. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aCoffin%2C+JM+%22Retroviruses%22">Retroviruses</a>. , Cold Spring Harbor Laboratory Press. (1997).</li>
<li>Li, M., Craigie, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Processing+of+viral+DNA+ends+channels+the+HIV-1+integration+reaction+to+concerted+integration%5BTitle%5D)+AND+%22J+Biol+Chem%22%5BJournal%5D)">Processing of viral DNA ends channels the HIV-1 integration reaction to concerted integration.</a> J Biol Chem. 280 (32), 29334-29339 (2005).</li>
<li>Li, M., Mizuuchi, M., Burke, T. R. Jr, Craigie, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Retroviral+DNA+integration%3A+reaction+pathway+and+critical+intermediates%5BTitle%5D)+AND+%22EMBO+J%22%5BJournal%5D)">Retroviral DNA integration: reaction pathway and critical intermediates.</a> EMBO J. 25 (6), 1295-1304 (2006).</li>
<li>Sinha, S., Grandgenett, D. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Recombinant+human+immunodeficiency+virus+type+1+integrase+exhibits+a+capacity+for+full-site+integration+in+vitro+that+is+comparable+to+that+of+purified+preintegration+complexes+from+virus-infected+cells%5BTitle%5D)+AND+%22J+Virol%22%5BJournal%5D)">Recombinant human immunodeficiency virus type 1 integrase exhibits a capacity for full-site integration in vitro that is comparable to that of purified preintegration complexes from virus-infected cells.</a> J Virol. 79 (13), 8208-8216 (2005).</li>
<li>Goodarzi, G., Im, G. J., Brackmann, K., Grandgenett, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Concerted+integration+of+retrovirus-like+DNA+by+human+immunodeficiency+virus+type+1+integrase%5BTitle%5D)+AND+%22J+Virol%22%5BJournal%5D)">Concerted integration of retrovirus-like DNA by human immunodeficiency virus type 1 integrase.</a> J Virol. 69 (10), 6090-6097 (1995).</li>
<li>Vora, A. C., Grandgenett, D. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Assembly+and+catalytic+properties+of+retrovirus+integrase-DNA+complexes+capable+of+efficiently+performing+concerted+integration%5BTitle%5D)+AND+%22J+Virol%22%5BJournal%5D)">Assembly and catalytic properties of retrovirus integrase-DNA complexes capable of efficiently performing concerted integration.</a> J Virol. 69 (12), 7483-7488 (1995).</li>
<li>Jones, N. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Retroviral+intasomes+search+for+a+target+DNA+by+1D+diffusion+which+rarely+results+in+integration%5BTitle%5D)+AND+%22Nat+Commun%22%5BJournal%5D)">Retroviral intasomes search for a target DNA by 1D diffusion which rarely results in integration.</a> Nat Commun. 7, 11409(2016).</li>
<li>JoVE Science Education Database. Basic Methods in Cellular and Molecular Biology. Separating Protein with SDS-PAGE. JoVE. , Cambridge, MA (2017).</li>
<li>Lee, P. Y., Costumbrado, J., Hsu, C. Y., Kim, Y. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Agarose+gel+electrophoresis+for+the+separation+of+DNA+fragments%5BTitle%5D)+AND+%22J+Vis+Exp%22%5BJournal%5D)">Agarose gel electrophoresis for the separation of DNA fragments.</a> J Vis Exp. (62), (2012).</li>
</ol>

The authors have nothing to disclose.

Recombinant proteins that interact with DNA, such as DNA repair proteins, oxygen scavengers for single molecule microscopy applications, or retroviral integrases, should be free of contaminating bacterial nucleases2,3. These contaminants may confuse the interpretation of results during bulk biochemical or single molecule assays.
We have found that a bacterial nuclease frequently co-purifies with PFV IN. However, PFV IN displays an affi...

Biochemical and single molecule studies of protein interactions with DNA require exceptionally pure recombinant proteins. Contaminating nucleases from bacteria can obscure the results of these assays. A contaminating nuclease has been found in preparations of recombinant proteins oxygen scavenger protocatechuate-3,4-dioxygenase (PCD) and prototype foamy virus (PFV) integrase (IN) isolated from Escherichia coli (E. coli)1,2,3.
Retroviral integration assays rely on the conversion of supercoiled DNA to nicked or linear products as a measure of IN activity4. During cellular infection IN joins the two ends of a viral cDNA to the host chromatin5. Each end joining reaction is termed strand transfer. Assays of recombinant IN activity may join two DNA oligomers mimicking the viral cDNA ends to a target DNA in a concerted integration reaction4,5,6,7,8. Alternatively recombinant IN may join only one DNA end in a non-physiologically relevant half site integration reaction9,10. When supercoiled plasmid DNA is the target of integration, concerted integration products are linearized DNA and half site integration products are relaxed circles. These reaction products are identified by their relative mobility during agarose gel electrophoresis1. If the recombinant IN has a contaminating nuclease, there will be spurious relaxed circles or a possibly linearized plasmid confusing the experimental results. Viral DNA oligomers may be fluorescently labeled to conclusively identify integration products, as opposed to nuclease products. However, IN greatly favors supercoiled DNA targets; any loss of supercoiled plasmid to relaxed circles or linear DNA by contaminating nuclease could skew results and interpretation of data11. Thus it is imperative to remove bacterial nucleases from retroviral IN preparations.
PFV IN has a different affinity for heparin sepharose compared to the bacterial nuclease1. PFV IN and the nuclease may be separated by a linear gradient elution from heparin sepharose. The nuclease is not readily detected by an ultraviolet (UV) absorbance at 280 nm peak or by analytical sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Instead, the nuclease is detected by a nuclease activity assay employing the conversion of a supercoiled plasmid to relaxed circles or linear products. Each fraction following heparin sepharose chromatography is tested for nuclease activity. PFV IN and the nuclease contaminant have no difference in affinity for Mono-Q anion resin. There is a small difference in affinity for Mono-S cation resin. However, the Mono-S resolution of bacterial nuclease and PFV IN would not allow efficient separation of the proteins. Ultimately, heparin sepharose affinity purification offers the best separation of bacterial nuclease from PFV IN and has the advantage of unlimited load volume.
Testing for contaminating nuclease activity may be adapted to other proteins. The protein of interest will likely have alternative affinity characteristics than PFV IN; the difference in binding characteristics of the protein of interest and the nuclease contaminant must be empirically determined. This methodology for identifying nuclease contamination may be adapted to other resins including Mono-S cation or Mono-Q anion exchange resins. Affinity and ion exchange resins may offer a reliable method to isolate a recombinant protein of interest from contaminating nucleases with no limits on the volume of protein during chromatography.

<table><tbody><tr><td>BL21/DE3 Rosetta E. coli</td><td>EMD Millipore</td><td>70956-4</td><td></td></tr><tr><td>LB broth</td><td>EMD biosciences</td><td>1.10285.0500</td><td></td></tr><tr><td>Ampicillin</td><td>Amresco</td><td>0339</td><td></td></tr><tr><td>Chloramphenicol&amp;nbsp;</td><td>Amresco</td><td>0230</td><td></td></tr><tr><td>PBS</td><td>Sigma-Aldrich</td><td>D8537</td><td></td></tr><tr><td>IPTG&amp;nbsp;</td><td>Denville Scientific</td><td>CI8280</td><td></td></tr><tr><td>ZnCl2</td><td>Sigma-Aldrich</td><td>208086</td><td></td></tr><tr><td>Tris Ultra Pure</td><td>Gojira Fine Chemicals</td><td>UTS1003</td><td></td></tr><tr><td>NaCl</td><td>P212121</td><td>RP-S23020</td><td></td></tr><tr><td>PMSF&amp;nbsp;</td><td>Amresco</td><td>0754</td><td></td></tr><tr><td>Imidazole&amp;nbsp;</td><td>Sigma-Aldrich</td><td>I0250</td><td></td></tr><tr><td>DTT&amp;nbsp;</td><td>P212121</td><td>SV-DTT</td><td></td></tr><tr><td>UltraPure EDTA</td><td>Invitrogen/Gibco</td><td>15575</td><td></td></tr><tr><td>MgSO&lt;sub&gt;4&lt;/sub&gt;</td><td>Amresco</td><td>0662</td><td></td></tr><tr><td>Agarose&amp;nbsp;</td><td>Denville Scientific</td><td>CA3510</td><td></td></tr><tr><td>Ethidium bromide</td><td>Thermo Fisher Scientific</td><td>BP1302</td><td></td></tr><tr><td>Glycerol</td><td>Fisher Scientific</td><td>G37-20</td><td></td></tr><tr><td>Ni-NTA Superflow</td><td>Qiagen</td><td>30430</td><td></td></tr><tr><td>Heparin Sepharose 6 Fast Flow</td><td>GE Healthcare Life Sciences</td><td>17-0998-01</td><td></td></tr><tr><td>HRV14 3C protease&amp;nbsp;</td><td>EMD Chemicals</td><td>71493-3</td><td></td></tr></tbody></table>

detection and removal of nuclease contamination during purification of recombinant prototype foamy virus integrase

Detection and Removal of Nuclease Contamination During Purification of Recombinant Prototype Foamy Virus Integrase

The integrase (IN) protein of the retrovirus prototype foamy virus (PFV) is a model enzyme for studying the mechanism of retroviral integration. Compared to IN from other retroviruses, PFV IN is more soluble and more amenable to experimental manipulation. Additionally, it is sensitive to clinically relevant human immunodeficiency virus (HIV-1) IN inhibitors, suggesting that the catalytic mechanism of PFV IN is similar to that of HIV-1 IN. IN catalyzes the covalent joining of viral complementary DNA (cDNA) to target DNA in a process called strand transfer. This strand transfer reaction introduces nicks to the target DNA. Analysis of integration reaction products can be confounded by the presence of nucleases that similarly nick DNA. A bacterial nuclease has been shown to co-purify with recombinant PFV IN expressed in Escherichia coli (E. coli). Here we describe a method to isolate PFV IN from the contaminating nuclease by heparin affinity chromatography. Fractions are easily screened for nuclease contamination with a supercoiled plasmid and agarose gel electrophoresis. PFV IN and the contaminating nuclease display alternative affinities for heparin sepharose allowing a nuclease-free preparation of recombinant PFV IN suitable for bulk biochemical or single molecule analysis of integration.

Recombinant PFV IN is often contaminated with a bacterial nuclease1. Biochemical integration assays depend on the quantitation of the conversion of supercoiled plasmid DNA to relaxed circles and linear products. The presence of a contaminating nuclease could lead to spurious quantitation of these assays. Expression of PFV IN with a hexahistidine tag is induced in E. coli (Figure 1) and first purified by nickel affinity chromatography (Fig...

Recombinant prototype foamy virus integrase protein is often contaminated with a bacterial nuclease during purification. This method identifies nuclease contamination and removes it from the final preparation of the enzyme.

The integrase (IN) protein of the retrovirus prototype foamy virus (PFV) is a model enzyme for studying the mechanism of retroviral integration. Compared ...

The overall goal of this protocol is to identify and remove contaminating nuclease activity during protein purification. This method can help answer key questions in the retrovirology field, such as biochemistry, structure, and dynamics of integration. The main advantage of this technique is that it allows identification and removal of contaminating DNA nuclease activity from a recombinant protein of interest during purification.Begin by thawing one pellet of E.coli expressing prototype foamy virus integrase on ice. Use a sonicator equipped with a 0.5-inch diameter biohorn with a 0.125-inch diameter tapered microtip to sonicate for 30 seconds at 30%amplitude with the tube on ice. After sonication, transfer the cell sample to a cold ultracentrifuge tube, and spin at 120, 000 times g for 60 minutes at four degrees Celsius.Following centrifugation, there should be an obvious pellet, and the supernatant may have a yellow color. Transfer the supernatant into a cold 50-milliliter conical tube. Next, set up the 110-millimeter long, five-millimeter diameter FPLC column with a 1.5 milliliter nickel-charged resin.First, connect the column to the FPLC instrument, and apply buffer. The instrument should be collecting real time data of conductivity and UV absorbance at 280 nanometers. The conductivity and UV readings should stabilize.If necessary, continue to flow buffers through the column until readings are stable. Using a superloop, load the protein sample onto the column at a flow rate of 0.15 milliliters per minute with a maximum pressure limit of 0.5 megapascal. Attach the superloop to the AKTA FPLC.After washing the column and eluting the proteins, pick 15-microliter aliquots of the initial flowthrough, wash, and peak 280-nanometer absorbance fractions, and add 15 microliters of 2X SDS-PAGE sample buffer to each sample. Boil the samples for three minutes. Load 10 microliters of each sample onto 10%SDS-PAGE gels, along with four microliters of pre-stained protein standards.Visually inspect the gel to identify fractions that appear to contain nearly pure prototype foamy virus integrase. Combine these fractions, and make a note of the volume while pipetting. This is typically eight to 10 milliliters.Using a spectrophotometer, measure the UV absorbance at 280 nanometers of the combined fractions, and calculate the total amount of prototype foamy virus integrase protein. A typical yield is around 10 milligrams per liter of induced culture. To remove the hexahistidine tag, supplement the prototype foamy virus integrase with a final concentration of 10-millimolar DTT and 0.1-millimolar EDTA.Then add 15 micrograms of human rhinovirus 3C protease per milligram of prototype foamy virus integrase, and incubate at four degrees Celsius overnight. To perform heparin affinity chromatography fractionation of the prototype foamy virus integrase, reduce the sodium chloride concentration of the sample to 200 millimolar by adding 1.5 volumes of buffer C. Then load the diluted prototype foamy virus integrase sample to the heparin Sepharose column at 0.5 milliliters per minute flow rate with a maximum pressure limit of one megapascal. After washing the column and collecting the gradient and final wash, analyze load, flowthrough, wash, and fractions by 8%SDS-PAGE.Then evaluate fractions by staining the gel with Coomassie blue. Prototype foamy virus integrase and the contaminating nuclease have different affinities for heparin Sepharose chromatography. Identify heparin Sepharose fractions that appear to contain nearly pure prototype foamy virus integrase to use in the nuclease assay.To begin the nuclease assay, combine three microliters of heparin fraction and 50 nanograms of three-kilobase supercoiled plasmid DNA and reaction buffer to a final volume of 15 microliters. Incubate at 37 degrees Celsius for 90 minutes. Stop the reaction with one milligram per milliliter Proteinase K and 0.5%SDS, and incubate at 37 degrees Celsius for one hour.Then add 3.5 microliters of 6X loading dye to the nuclease assay reactions, and load the entire volume on a 1%agarose gel. Run the gel at 100 volts at ambient temperature for one hour or until the dye front reaches the end of the gel. When electrophoresis is complete, a fluorescent scanner image of the gel should show that linear DNA runs true to size at three kb, supercoiled DNA runs faster to around two kb, and that relaxed circle DNA runs slower at close to 3.5 kb.Using image analysis software, calculate the pixel volume of the supercoiled, linear, and relaxed circle plasmid in each lane. Call the sum of the pixel volumes for these three DNA forms the total DNA value, and use it to calculate the percentage of linear and relaxed circles. Fractions that contain contaminating nuclease display a higher percentage of linear and relaxed circles compared to the negative control.Combine the heparin Sepharose fractions that do not display contaminating nuclease activity, and transfer to 10 millimeter, six to eight kilodalton molecular weight cut-off dialysis tubing. Dialyze at four degrees Celsius overnight against one liter of dialysis solution. The next day, recover the nuclease-free prototype foamy virus integrase sample from the dialysis tubing.Measure the absorbance at 280 nanometers, and calculate the final protein concentration. Aliquot the protein, and snap freeze in liquid nitrogen. Then store the aliquots at minus 80 degrees Celsius.The nuclease assay was performed as outlined in this video. Negative controls include plasmid DNA with no protein and a previous purification of wild-type prototype foamy virus integrase known to be free of nuclease. A positive control for contaminating nuclease activity is a previous purification of catalytically inactive prototype foamy virus integrase that is known to have contaminating nuclease.Following this procedure, other methods, like biochemical assays or single molecule imaging, can be performed in order to answer additional questions, like enzyme kinetics and dynamics. After watching this video, you should have a good understanding of how to identify and remove contaminating nuclease activity from a recombinant protein.

detection-removal-nuclease-contamination-during-purification

Research

JoVE Journal

Immunology and Infection

The genome of the influenza A virus consists of eight separate complexes of RNA and proteins, termed viral ribonucleoprotein complexes (vRNPs). This paper describes the glycerol gradient purification and transmission electron microscopy visualization of influenza A vRNPs.

Purification and Visualization of Influenza A Viral Ribonucleoprotein Complexes

Structure-based drug design plays an important role in drug development.  Pursuing multiple targets in parallel greatly increases the chance of success for lead discovery. The following article highlights how the Seattle Structural Genomics Center for Infectious Disease utilizes a multi-target approach for gene-to-structure determination of the PB2 influenza A subunit.

Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit

Source: Yuan, M., et al. A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors. J. Vis. Exp. (2016)This video demonstrates the process of performing a fluorescent plaque assay using recombinant vaccinia virus encoding red fluorescent protein (RFP) in fibroblast cells, followed by plaque isolation and purification for further analysis.

Fluorescence-Based Detection and Purification of Recombinant Vaccinia Virus

We describe a protocol for amplifying retroviral integration sites from the genomic DNA of infected cells, sequencing the amplified virus-host junctions, and then mapping these sequences to a reference genome. We also describe techniques to quantify the distribution of integration sites relative to various genomic annotations using BEDTools.

Amplification, Next-generation Sequencing, and Genomic DNA Mapping of Retroviral Integration Sites

This manuscript describes the experimental procedure and software analysis for a bidirectional integration site assay that can simultaneously analyze upstream and downstream vector-host junction DNA. Bidirectional PCR products can be used for any downstream sequencing platform. The resulting data are useful for a high-throughput, quantitative comparison of integrated DNA targets.

Bidirectional Retroviral Integration Site PCR Methodology and Quantitative Data Analysis Workflow

The goal of this protocol is to specifically tag and selectively isolate viral DNA from infected cells for the characterization of viral genome associated proteins.

Purification of Viral DNA for the Identification of Associated Viral and Cellular Proteins

Recombinant retroviral integrase and DNA oligomers mimicking viral DNA ends can form an enzymatically active complex known as an intasome. Intasomes may be used for biochemical, structural, and kinetic studies. This protocol details how to assemble and purify prototype foamy virus intasomes.

Assembly and Purification of Prototype Foamy Virus Intasomes

We describe here the in vitro generation of HBV DNA via a Hepatitis B virus infection system and the highly sensitive detection of its (1–2 copies) integration using inverse nested PCR.

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

This manuscript describes a detailed protocol for the generation and purification of adeno-associated viral vectors using an optimized heparin-based affinity chromatography method. It presents a simple, scalable, and cost-effective approach, eliminating the need for ultracentrifugation. The resulting vectors exhibit high purity and biological activity, proving their value in preclinical studies.

Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol

Insertional mutagenesis is an essential tool in forward genetics for identifying functional genomic elements. Here, we describe the Insertion-based Screen for functional Elements and Transcripts (InSET), a method for detecting lentivirus integration sites within a lentivirus-based insertional mutagenesis cell library.

Identification of Functionally-Relevant Lentivirus Integration Sites in an Insertional Mutagenesis Cell Library

This protocol describes a gel shift biochemical assay for measuring FEN1 (Flap Endonuclease 1) activity and inhibitor development.

Fluorescence-Based Detection of FEN1 Nuclease Activity and Screening of Small-Molecule Inhibitors

Learn to detect and remove nuclease contamination during purification of recombinant prototype foamy virus integrase from Escherichia coli. This protocol uses heparin affinity chromatography and a nuclease assay to ensure nuclease-free protein for accurate biochemical and single-molecule studies of retroviral integration.

Detection and Removal of Nuclease Contamination During Purification of Recombinant Prototype Foamy Virus Integrase

Explore More Videos